41 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Shandong University
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina At Chapel Hill
Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2.
University of Copenhagen
Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.
Sapienza University of Rome
Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line.
Universidade De Vigo
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
TBA
Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
Imperial College
Development of rationally designed DNA N6 adenine methyltransferase inhibitors.
University of Southampton
Synthesis and biochemical evaluation ofd(2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors.
Universit£
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
Deutsches Krebsforschungszentrum
Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors.
Methylgene
SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes.
Methylgene
Discovery of two novel, small-molecule inhibitors of DNA methylation.
Polish Academy of Sciences
Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.
Victoria University of Wellington
Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Emory University School of Medicine
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
University of Navarra
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Southern Medical University
Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
University of Michigan Medical School
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
University College London
Synthesis of NSC 106084 and NSC 14778 and evaluation of their DNMT inhibitory activity.
Universit£
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
The University of Texas M.D. Anderson Cancer Center
Identification of novel quinazoline derivatives as potent antiplasmodial agents.
Universit£
Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
National University of Singapore
Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1.
Universit£
Design, synthesis and in vitro anti-Zika virus evaluation of novel Sinefungin derivatives.
Chinese Academy of Medical Sciences and Peking Union Medical College
Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening.
Chinese Academy of Sciences
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
Wuxi Apptec (Tianjin) Co.
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Universidad De Oviedo-Principado De Asturias
Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells.
Cnrs-Pierre Fabre Usr3388
